New strategic agreements with the medicines industry – PBS website updates

1 July 2022 - Amendments made by the National Health Amendment (Enhancing the Pharmaceutical Benefits Scheme) Act 2021 give effect to ...

Read more →

Breaking the rule of drug pricing In America

29 June 2022 - Having worked in healthcare most of my life, very little surprises me. But four years ago, ...

Read more →

IP waiver for COVID vaccines is a threat to future innovation

20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have ...

Read more →

Drug pricing debate in Washington is a headache for pharma

17 June 2022 - Last-ditch effort by Democrats to pass slimmed-down version of Build Back Better could include measures on drug ...

Read more →

IP waiver for COVID vaccines misses the mark in vaccinating the world

14 June 2022 - Vaccinating the world remains a priority and proposals to weaken the intellectual property for COVID-19 vaccines ...

Read more →

Harvard professors continue to push misconceptions to justify drug price controls

10 June 2022 - The biopharmaceutical industry performed wonderfully during the COVID-19 pandemic.  ...

Read more →

Takeda says drug makers could cut prices in face of global crises

30 May 2021 - The head of Asia’s largest pharmaceutical company said the risk of a global recession, along with ...

Read more →

Japan pharma lobbies say pricing scheme leading to renewed 'drug lag'

16 May 2022 - Japan's three major pharmaceutical lobbies joined for the first time on Monday in urging reforms to ...

Read more →

The man behind ‘value based pricing’ saw pharma distorting his message — and walked away

13 May 2022 - When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company gave ...

Read more →

Is it best to remove insurance benefits from drugs prescribed in bribery?

25 April 2022 - The Ministry of Health and Welfare’s Health Insurance Policy Review Committee is scheduled to hold a ...

Read more →

Supply related data in manufacturer dossiers: things are not going smoothly yet

19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science.  ...

Read more →

Update to the statutory scheme to control the costs of branded health service medicines

15 March 2022 - The UK Government is seeking views on its proposal to increase the rate of payments made ...

Read more →

Drug industry says EMA’s PRIME scheme useful but could be improved

14 March 2022 - Eligibility criteria for admission to the EMA's priority medicines (PRIME) scheme are too strict to facilitate ...

Read more →

PhRMA Statement on the State of the Union Address

1 March 2022 - The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the ...

Read more →

MAP offers new online pathway for accessing cancer treatments

25 February 2022 - Medicines Australia and Rare Cancers Australia yesterday provided pharmaceutical industry stakeholders a preview of a new ...

Read more →